The FDA has approved an adjuvant combination of pembrolizumab and belzutifan for high-risk clear cell kidney cancer after surgery, adding a hypoxia-axis HIF-2α inhibitor to standard immune checkpoint strategies. The approval covers eligible adults with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy and reinforces the growing role of HIF-2α targeting in RCC. Separately, Merck’s Welireg plus Keytruda was cleared for this adjuvant setting, signaling regulator acceptance of the dual mechanism in earlier-stage disease rather than only metastatic contexts. For clinicians and payers, the decision expands treatment sequencing options in post-operative oncology care and may affect comparative choices versus other adjuvant immunotherapy backbones. The adjuvant label update is likely to drive additional prescriber and trial activity around biomarker-driven selection between RCC regimens, particularly where hypoxia biology is implicated in recurrence risk.